D7014ZZ
Beam Radiation Thymus to None with None, Heavy Particles (Protons,Ions) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 7 Lymphatic and Hematologic System |
| Operation | 0 Beam Radiation |
| Body Part | 1 Thymus |
| Approach | 4 Heavy Particles (Protons,Ions) |
| Device | Z None |
| Qualifier | Z None |
Procedure Overview
Beam radiation to the lymphatic and hematologic system delivers external radiation, typically from a linear accelerator, to lymph node regions or hematologic tissue affected by cancers such as Hodgkin lymphoma, non-Hodgkin lymphoma, or localized involvement from leukemia. Treatment is usually planned as a fractionated course given over several weeks, with the total dose divided into smaller daily sessions to maximize tumor control while allowing normal tissue to recover between treatments.
It is used both as primary therapy for certain lymphomas confined to specific nodal regions and as consolidation after chemotherapy to eliminate residual disease in previously bulky sites. Patients typically receive planning imaging beforehand to map the treatment field precisely to the involved nodal chain.
Anatomy & Axis Detail
Thymus
The thymus, a lobed gland in the anterior mediastinum behind the sternum, is central to T-lymphocyte maturation during childhood and gradually involutes with age, but it can be the site of thymoma, thymic carcinoma, or thymic hyperplasia associated with myasthenia gravis. Beam radiation to the thymus is used as adjuvant therapy after incomplete resection of a thymic tumor, for unresectable disease, or occasionally in combination with thymectomy for refractory myasthenic disease. Its close proximity to the heart, great vessels, lungs, and esophagus makes careful field shaping essential to limit cardiopulmonary dose, particularly in younger patients for whom long-term toxicity is a greater concern. Documentation should specify the mediastinal target and, when relevant, note whether treatment follows surgical thymectomy.
Modality Qualifier: Heavy Particles (Protons,Ions)
Heavy Particles (Protons, Ions) covers particle-beam radiotherapy using protons or heavier charged ions, which exhibit a Bragg peak that concentrates dose at a specific depth with minimal exit dose beyond the target. This property distinguishes it from conventional photon or electron beams, which continue to deposit dose along their path, and makes heavy particle therapy attractive for tumors near critical structures like the spinal cord or optic pathways.
Coding & Documentation
Coders need documentation specifying the treatment site (a named lymph node region, spleen, or other hematologic structure), the modality as external beam, and the qualifier describing the type of beam, such as photon or electron therapy, drawn from the radiation oncology treatment plan and daily treatment records.
A common error is coding the diagnosis-driven anatomic site rather than the actual field treated, since radiation fields are often described in oncology shorthand like "mantle field" or "involved-site radiotherapy" that must be translated to the correct body part value. Failing to capture the correct qualifier for beam type is another frequent gap when the treatment summary isn't reviewed closely.